31-45 of 775
Recognizing the Burden of Paroxysmal Nocturnal Hemoglobinuria
Project Oncology®Recognizing the Burden of Paroxysmal Nocturnal Hemoglobinuria
Examining Unmet Needs in Paroxysmal Nocturnal Hemoglobinuria
Project Oncology®Examining Unmet Needs in Paroxysmal Nocturnal Hemoglobinuria
Examining the Treatment Paradigm for Paroxysmal Nocturnal Hemoglobinuria
Project Oncology®Examining the Treatment Paradigm for Paroxysmal Nocturnal Hemoglobinuria
Managing PNH Patients: Addressing the Unmet Needs
Project Oncology®Managing PNH Patients: Addressing the Unmet Needs
- advertisement
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Heart MattersNavigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
Project Oncology®10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Project Oncology®Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Project Oncology®Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Project Oncology®Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
- advertisement
Real-World CDK4/6 Inhibitor Patterns in HR+/HER2– Metastatic Breast Cancer
Project Oncology®Real-World CDK4/6 Inhibitor Patterns in HR+/HER2– Metastatic Breast Cancer
Selecting First-Line Therapy in Gastric Cancers: A Biomarker-Driven Approach
Project Oncology®Selecting First-Line Therapy in Gastric Cancers: A Biomarker-Driven Approach
Assessing Atirmociclib Plus Letrozole in HR+/HER2- Metastatic Breast Cancer
Project Oncology®Assessing Atirmociclib Plus Letrozole in HR+/HER2- Metastatic Breast Cancer
